Job Spectrum

Notwithstanding a frail economy, America's pharmaceutical research and biotechnology corporations invested a record $65.3 bn. last year in the analysis and development of new life-changing drugs and vaccines an increase of more than $1.5 bn. from 2008, according to analyses by the Pharmaceutical Research and producers of America and Burrill & Company.

This investment reflects the ongoing commitment of America's biopharmaceutical research corporations to steer the world in the pursuit of new, life-saving and life-enhancing drugs. PhRMA-member corporations alone spent an approximate $45.8 bln on pharmaceutical RD last year, according to the PhRMA survey. The Burrill & Company research shows that non-PhRMA pharmaceutical research firms in the US spent an approximate $19.5 bn.on RD in 2009.

Investment in RD by America's pharmaceutical research and biotechnology firms stayed robust last year, in the face of a weak commercial environment and traditionally low expansion in drug spending. While corporations have been made to make tough business choices, research spending as a proportion of sales stayed high in 2009. Over the last 9 years, America's pharmaceutical research firms have regularly invested around eighteen % of domestic sales on RD activities.

"America's biopharmaceutical research sector takes great pride in its world leadership in the development of new life-saving treatments and cures, " said PhRMA President and Manager Billy Tauzin. "over the last year the economic challenges have been giant, but our industry's continued commitment to RD is bringing hope to millions of patients around the world who are fighting doubtless devastating illnesses like cancer, heart problems and diabetes.

" U.S.Biopharmaceutical firms' concentrate on research has been noted by many independent gurus. As an example, the nonpartisan Congressional Budget Office ( CBO ) has announced : "The pharmaceutical sector is among the most research-intensive industries in the U. S. . Pharmaceutical firms invest as much as five times more in research and development, relative to their sales, than the average U.S. Producing firm.

"Last year, Varsity of Connecticut analysts likewise revealed that during the last twenty-five years, investment in RD by the pharmaceutical and biotechnology sectors considerably surpassed that of all the other industries in the U.S.

Importantly, this investment has produced results. According to a 2006 CBO research, "Many examples exist of major healing gains attained by the industry in fresh years.... [A]necdotal and probabilistic evidence implies the quick increases that've been noted in drug-related RD spending have been accompanied by major healing gains in available drug treatments.

"As an example, independent analysis shows that cancer patients are living, normally 3 years more and 83 percent of those survival rate gains are due to new treatments, including drugs. Cardiac arrest and coronary deaths dropped by almost half from 1999 to 2005. And since the arrival of highly active anti-retroviral care in 1995, the once a year number of U.S. Deaths due to AIDS has plunged by at least seventy p.c.

As in years gone by, a rising number of potential new drugs are entering clinical testing.Today, there are far more than 2,900 drugs in clinical tests or waiting for review by the Food and Drug Administration in the U.S, compared with 2,400 in 2005. The prevailing pipeline includes more than eight hundred drugs to treat cancer, over three hundred precise to rare illnesses and more than three hundred drugs for heart problems and stroke.

"This exciting research not only carries the ability to significantly change and improve the lives of numerous patients, it supports valuable and rewarding roles for millions of American workers, " related Tauzin. "With rates of joblessness remaining high, our country must embrace robust sectors like ours. If we would like to maintain our leadership in biopharmaceutical RD and the successive worth it brings to our state and state economies it's imperative the U.S.Preserve policies which make such research possible.

"The Pharmaceutical Research and producers of America ( PhRMA ) represents the country's leading pharmaceutical research and biotechnology firms, which are dedicated to inventing drugs that permit patients to live for longer, more fit, and more profitable lives. PhRMA firms are leading the way in the quest for new cures.PhRMA members alone invested a projected $45.8 bn. in 2009 in finding and developing new drugs. Industry-wide research and investment reached a record $65.3 billion in 2009.